KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) Operating Income (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Operating Income for 17 consecutive years, with -$118.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Income fell 303.84% to -$118.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $47.2 million, a 82.45% decrease, with the full-year FY2025 number at $47.2 million, down 82.45% from a year prior.
  • Operating Income was -$118.9 million for Q4 2025 at Bio-Rad Laboratories, down from $65.3 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $156.8 million in Q3 2021 to a low of -$118.9 million in Q4 2025.
  • A 5-year average of $82.1 million and a median of $92.8 million in 2022 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: surged 141.16% in 2021, then crashed 303.84% in 2025.
  • Bio-Rad Laboratories' Operating Income stood at $117.9 million in 2021, then increased by 7.02% to $126.2 million in 2022, then dropped by 24.45% to $95.3 million in 2023, then tumbled by 38.81% to $58.3 million in 2024, then plummeted by 303.84% to -$118.9 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Operating Income are -$118.9 million (Q4 2025), $65.3 million (Q3 2025), and $77.1 million (Q2 2025).